使用闭环系统qRT-PCR观测的PD-L1和PD-L2 mRNA与免疫疗法治疗的非小细胞肺癌的预后有关，并具有较高的阴性预测价值

Results 结果

Both high PD-L1 and PD-L2 mRNA expression levels were associated with improved long-term benefit at 24 months (p=0.047 for both PD-L1 and PD-L2) and overall survival (PD-L1, p= 0.048; PD-L2 p= 0.049). Both PD-L1 and PD-L2 mRNA levels were higher in patients with KRAS mutations. Most importantly, low PD-L1 mRNA showed a high negative predictive value of 0.92 for absence of long-term benefit.

颇高的PD-L1和PD-L2 mRNA表述水平都与24个月的长期获益（PD-L1和PD-L2的p=0.047）和总死亡率（PD-L1，p=0.048；PD-L2 p=0.049）的优化有关。在KRAS特异性的病人里面，PD-L1和PD-L2的mRNA水平都尤其颇高。最重要的是，偏高的PD-L1 mRNA标示出出很颇高的阴性分析值，即0.92，说明并未长期得益。

Conclusions 假设

With further validation this assay in low stage patients, assessment of PD-L1 mRNA rather than protein, could be a method to determine which low stage patients should not be treated with ICIs in the adjuvant setting. This approach may also be a useful objective method for selecting patients for treatment in the advanced setting.

随着更进一步的的测试，这种对晚期病人的的测试，对PD-L1 mRNA而不是蛋白质的评估，可以成为具体哪些偏高期病人不应当在辅助病患里面采用ICIs的作法。这种作法也可能是一种精确的客观作法，用于选择后半期病人的病患。

本文转载自其他网站，不代表肥胖症基本要素论据和立场。如有内容和图像的著作权辩解，请求适时联系我们（邮箱：guikequan@hmkx.cn）